Compare Autodesk Inc (ADSK) vs Amgen, Inc. (AMGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Autodesk Inc vs Amgen, Inc. — how do they compare? Autodesk Inc trades at $206.41 (market cap $44.84B), while Amgen, Inc. trades at $367.5 (market cap $198.67B). The key difference: Amgen, Inc. is far larger — about 4.4× Autodesk Inc's market cap, and Amgen, Inc. pays a 2.74% dividend while Autodesk Inc pays none. Which is the better fit depends on your goals.
| ADSK | AMGN | |
|---|---|---|
Market Cap | $44.84B | $198.67B |
Sector | Technology | Health |
52-Week High | $326.79 | $388.16 |
52-Week Low | $187.72 | $271.18 |
Enterprise Value | $44.64B | $243.95B |
Dividend Yield | — | 2.74% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
